HIMS accelerates global growth with ZAVA buyout, Canadian launch, and soaring EPS estimates pointing to 177.8% upside.

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The BUZZ Index returned 12.68% during the month of June compared to a return of 5.09% for the S&P 500 Index during the same ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

Quest Diagnostics ranks first in Revenue Growth among its peers. It is second in Gross Profit and Return on Equity. The ...

In a cultural climate where the definition of masculinity is more complex than ever, men’s wellness brands are evolving to ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Hims & Hers Health, Inc. (HIMS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

The overall sentiment of these big-money traders is split between 31% bullish and 50%, bearish. Out of all of the special options we uncovered, 3 are puts, for a total amount of $106,898, and 13 are ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...